Grifols saves Spanish Alzheimer's vaccine developer Araclon
This article was originally published in Scrip
Executive Summary
Spanish plasma derivatives producer Grifols has stepped in to save Araclon Biotech, a spin-off of the Spanish University of Zaragoza in Aragon which is developing an immunotherapy for Alzheimer's disease as well as early diagnosis kits for the disease. Grifols has taken a 51% shareholding in the company through its investment vehicle, Gri-Cel, which it set up in 2010 to enable it to get involved in new fields of medicine which lie outside the main focus of its activities.
You may also be interested in...
20 Voices: What Does 2024 Hold For Biopharma?
20 executives in the biopharma industry outline their view of key trends this year. A selection of commentary from a broad industry survey by Scrip.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances
More than 100 biopharma executives and experts told Scrip their predictions for therapeutic area advances in the coming year. The recent commercial success of GLP-1s in diabetes and obesity and their potential in further disease areas fuelled excitement around the metabolic space. Expectations were also positive in neurology following the launch of Leqembi for Alzheimer’s disease in 2023, while the multiple opportunities to improve cancer treatment kept oncology top of the pile overall.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 5: Clinical Trial Trends
Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.